Vaxart Inc
VXRT.O- Latest Trade
- trading lower0.75USD
- -0.01
- 0.99%
- As of Mar 28 2023. Values delayed up to 15 minutes
- Today's Range
- 0.75 - 0.78
- 52 Week Range
- 0.70 - 5.32
- Previous Close
- 0.76
- Open
- 0.76
- Volume
- 495,404.00
- 3 Month Average Trading Volume
- 36.10
- Shares Out (Mil)
- 135.56
- Market Cap
- 102.67
- Forward P/E
- -0.98
- Dividend Yield
- 0.00
Key Statistics
2.00 mean rating - 4 analysts
- P/E Excl. Extra Items (TTM)
- 0.00
- Price To Sales (TTM)
- 959.57
- Price To Book (Quarterly)
- 0.92
- Price To Cash Flow (Per Share TTM)
- 0.00
- Total Debt/Total Equity (Quarterly)
- 0.00
- Long Term Debt/Equity (Quarterly)
- 0.00
- Return On Investment (TTM)
- -62.23
- Return On Equity (TTM)
- -57.47
2021 (millions USD)
About Vaxart Inc (VXRT.O)
Company Information
Vaxart, Inc. is a clinical-stage biotechnology company that is primarily focused on the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) oral vaccine platform. Its programs include tablet vaccines designed to protect against coronavirus, norovirus, seasonal influenza and respiratory syncytial virus (RSV), as well as a therapeutic vaccine for human papillomavirus (HPV). The Company’s product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection. The Company is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus.
Address
170 Harbor Way, Suite 300SOUTH SAN FRANCISCO, CA
94080
United States
Industry
Biotechnology & Drugs
Executive Leadership
- Todd C. Davis
- Independent Chairman of the Board
- Andrei Floroiu
- President, Chief Executive Officer, Director
- Phillip E. Lee
- Chief Financial Officer, Chief Accounting Officer
- Sean N. Tucker
- Senior Vice President, Chief Scientific Officer
- Edward B. Berg
- Senior Vice President, General Counsel
- Raymond D. Stapleton
- Chief Technology Officer
- James F. Cummings
- Chief Medical Officer
- W. Mark Watson
- Director
- Michael J. Finney
- Independent Director
- Elaine J. Heron
- Independent Director
- David E. Wheadon
- Independent Director
- Robert A. Yedid
- Independent Director
Latest News
Financials
Source: Refinitiv, an LSEG business - data delayed by at least 15 minutes
Markets Performance
Official Data PartnerCommodities
| Future | Last | % Change |
|---|---|---|
| Gold | 1,952.40 | -- |
| Copper | 789.50 | 0.80% |
| Brent Crude Oil | 78.99 | 1.11% |
| CBOT Soybeans | 1,463.50 | 1.47% |
Stocks
| Index | Last | % Change |
|---|---|---|
| S&P 500 | 3,969.81 | 0.19% |
| Euro STOXX 50 | 4,168.21 | 0.09% |
| FTSE 100 | 7,484.25 | 0.17% |
| Nikkei 225 | 27,518.25 | 0.15% |
Source: Refinitiv, an LSEG business - data delayed by at least 15 minutes